10 years have passed since the launch of Bovela ®. A decade providing value through innovation thanks to a product that offers the efficacy of a live vaccine and the safety of an inactivated vaccine against BVD.
Since then, with more than 30 million doses worldwide, Bovela ® continues to set the standard for technological innovation in vaccination against BVD and is the only monovalent live vaccine against the disease in Spain.
With these credentials, Bovela ® capitalized on the participation of Boehringer Ingelheim Animal Health Spain in the XXVII Anembe International Congress of Bovine Medicine. A reference event in the sector that brought together more than 800 professionals in the city of Vitoria from May 28 to 30 and which, once again, was sponsored by the company.
The perfect forum for knowledge exchange
The importance of this established event and the level of its scientific program make it, edition after edition, a forum for the exchange and updating of knowledge for professionals in the cattle sector.
For this reason, the congress was the chosen place for the presentation of the new Bovela ® campaign, which emphasizes that due to its efficacy and safety, the vaccine has demonstrated over the years that no false steps can be taken in the control of BVD.
If you’re interested: Technical sheet Bovela ®
If you want to know more, visit the official website of Boehringer Ingelheim
Continue reading this content
Register for free or log in to access all rumiNews content.
